"MIB","MAB" & "NIB" News
*As per Medscape:
February 2, 2009 — Trastuzumab (Herceptin, Roche) has been approved for use in the treatment of HER2-positive gastric cancer by the European Commission. This is the first approval in the world for this label extension for trastuzumab, which is already marketed for use in the treatment of HER2-positive breast cancer.*As per OncoSTAT:
A new drug has been found to slow the progression of advanced kidney cancer. The drug, pazopanib, was tested in a phase III study among 435 patients...Pazopanib targets multiple pathways involved in cancer cell growth and is an angiogenesis inhibitor. The drug is administered orally. Using supportive evidence from this study, the Food and Drug Administration approved pazopanib in October 2009 for the treatment of advanced renal cell carcinoma. The research results were published in the January 25 online issue of the Journal of Clinical Oncology.
*Also from OncoSTAT:
CORONADO, Calif. (EGMN) - Smokers with metastatic non-small cell lung cancer were able to tolerate much higher doses of the targeted therapy erlotinib than were their nonsmoking counterparts in a small, ongoing phase II clinical trial.
0 comments:
Post a Comment